Comparison of Pitavastatin With Atorvastatin in Increasing High Density Lipoprotein - Cholesterol (HDL-C) and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease (CAD)

Comparison of Pitavastatin With Atorvastatin in Increasing HDL-C and Adiponectin in Patients With Dyslipidemia and Coronary Artery Disease.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00861861

Acronym

COMPACT-CAD

Enrollment

129

Registered

2009-03-16

Start date

2008-09-30

Completion date

2013-10-31

Last updated

2013-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease, Hypercholesterolemia

Keywords

Pitavastatin, Atorvastatin, CAD, HDL-C, Adiponectin

Brief summary

The purpose of this study is to compare the effects of pitavastatin and atorvastatin on adiponectin percentage change in patients with hypercholesteremia comorbid stable CAD.

Detailed description

The efficiency of lipid lowering therapy was already proven by the clinical trials of statins. According to these results, the target value of LDL-C is recommended under 100mg/dL in the Japan Atherosclerosis Society Guidelines. However, the efficiency of intensive therapy to lower LDL-C more than 100mg/dL has not been proven yet.

Interventions

DRUGPitavastatin

comparison of two drugs in increasing HDL-C and adiponectin

DRUGAtorvastatin

comparison of two drugs in increasing HDL-C and adiponectin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 85 Years

Healthy volunteers

Inclusion criteria

* Patients with dyslipidemia as defined by any of the parameters: * HDL-C \< 50 mg/dL * LDL-C ≥ 140 mg/dL * LDL-C ≥ 100 mg/dL and cholesterol-lowering treatment is necessary in accordance with the investigator's judgement * Patients who passed three months or more after acute myocardial infarction * Patients who passed one month or more after unstable angina * Patients who passed one month or more after PCI * Patients with written consent by their own volition after being provided sufficient explanation for the participation into this clinical trial

Exclusion criteria

* Patients with any allergy to pitavastatin or atorvastatin * Patients with familial hypercholesterolemia * Patients receiving pitavastatin * Patients with severe hypertension * Patients with renal disorders or undergoing dialysis * Patients with hepatobiliary disorders * Patients with hepatobiliary disorders * Patients with family history of hypothyroidism or muscular dystrophy * Patients with history of drug-induced hepatic disorder * Drug abuser or dipsomaniac * Patients with cardiogenic shock. * Patients who hopes for pregnancy during this study * Contraindications, Relative Contraindications, Absolute Contraindications for Coadministration and Relative Contraindications for Coadministration for pitavastatin or atorvastatin * Patients who are ineligible in the opinion of the investigator

Design outcomes

Primary

Measure	Time frame
HDL-cholesterol (HDL-C); Adiponectin; High-Molecular- Weight Adiponectin(HMW Adiponectin)	start, 6 months, 12 months, 30 months

Secondary

Measure	Time frame
TC; LDL-C; HDL-C; HDL2-C; HDL3-C; TG; smalldenseLDL; MDA-LDL; FPG; HbA1c; Cr; RLP-C; apoA-I; apoB; apoC-Ⅱ; apoC-Ⅲ	start, 6 months, 12 months, 30 months

Countries

Japan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026